Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Mesoblast Limited ( (AU:MSB) ) has shared an announcement.
Mesoblast Limited announced the presentation of Ryoncil, the first FDA-approved mesenchymal stromal cell therapy, at the ISCT. This approval marks a significant milestone for the company, potentially enhancing its industry positioning and offering promising implications for stakeholders involved in the development and commercialization of stem cell therapies.
More about Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines, focusing on treatments for inflammatory diseases. The company is known for its pioneering work in mesenchymal stromal cell therapy, with a market focus on developing innovative stem cell technologies.
YTD Price Performance: 21.82%
Average Trading Volume: 281,886
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $1.6B
For detailed information about MSB stock, go to TipRanks’ Stock Analysis page.